| International Session（Symposium）6(JSGE・JGES・JSGS・JSGCS) |
| Fri. November 6th 9:00 - 12:00 Room 11: Portopia Hotel South Wing Topaz |
| Recent advancement in pancreatic cancer | |||
| Do-Youn Oh1,2 | |||
| 1Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, 2Cancer Research Institute, Seoul National University College of Medicine | |||
|
|||
|
|||
| Pancreatic cancer is projected to be the third leading cause of cancer-related death by 2030. Multiple factors contribute to this dismal prognosis, including late diagnosis, treatment resistance and lack of personalized treatment stratification so far. Mutational landscape of pancreatic cancer is being uncovered. KRAS, ROBO-SLIT pathway, RNA Processing, cell cycle, DNA repair, TGF beta signaling, NOTCH signaling, WNT signaling, chromatin, and SWI/SNF alteration are the important categories of this molecular changes. With the development of tumor biology and precision medicine methodology, pancreatic ductal adenocarcinoma is being subtyped, such as Collisson’s subtype, Moffitt’s subtype, Bailey’s subtype, etc. The translation of these molecular classifications into clinical practice could help the realization of precision medicine in pancreatic cancer. Parallel with recent successes with cytotoxics (nab-paclitaxel, nanoliposomal irinotecan), interesting therapeutic targets have been emerged in pancreatic cancer and have been targeted by interesting agents in clinical trials. In germline BRCA mutant pancreatic cancer, olaparib, PARP inhibitor, has improved progression-free survival as used for maintenance treatment after platinum-based chemotherapy. This is the first success of precision medicine in pancreatic cancer. The idea of harnessing immune cells to fight cancer is not new, but only recently have scientist amassed enough clinical data to demonstrate what a game-changer cancer immunotherapy can be. Immuno-oncology agents are also being tested in pancreatic cancer, many of which are in the combination strategy. |
|||
|
Index Term 1: pancreatic cancer Index Term 2: systemic treatment |
|||
| Page Top | |||